DGS Capital Management’s Royalty Pharma RPRX Stock Holding History

DGS Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$260K	Buy	+5,417	New	+$237K	0.04%	445

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DGS Capital Management's RPRX Position: Q1 2026 in Review

DGS Capital Management opened a new position in Royalty Pharma (RPRX) in Q1 2026: 5,417 shares worth $260K. The stake represents 0.04% of the portfolio and ranks #445 among its holdings.

591 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

DGS Capital Management held 5,417 shares of Royalty Pharma worth $260K as of Q1 2026.
Royalty Pharma was a new DGS Capital Management position in Q1 2026.
Royalty Pharma made up 0.04% of DGS Capital Management's portfolio in Q1 2026, its #445 holding.
591 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.